Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $512,989 | $468,269 | $438,906 | $727,848 |
| - Cash | $297,263 | $381,393 | $155,385 | $183,259 |
| + Debt | $554,948 | $139,030 | $97,070 | $91,341 |
| Enterprise Value | $770,674 | $225,906 | $380,591 | $635,930 |
| Revenue | $55,252 | $682 | $0 | $0 |
| % Growth | 8,001.5% | – | – | – |
| Gross Profit | $47,279 | $515 | -$620 | -$521 |
| % Margin | 85.6% | 75.5% | – | – |
| EBITDA | -$261,522 | -$159,049 | -$169,798 | -$136,574 |
| % Margin | -473.3% | -23,321% | – | – |
| Net Income | -$334,326 | -$201,592 | -$197,723 | -$143,883 |
| % Margin | -605.1% | -29,558.9% | – | – |
| EPS Diluted | -5.29 | -3.93 | -5.7 | -4 |
| % Growth | -34.6% | 31.1% | -42.5% | – |
| Operating Cash Flow | -$266,770 | -$137,580 | -$146,530 | -$148,457 |
| Capital Expenditures | -$135 | -$1,634 | -$1,041 | -$328 |
| Free Cash Flow | -$266,905 | -$139,214 | -$147,571 | -$148,785 |